product candidate, Allovectin-7(R), the
HIV vaccine candidate, the RapidResponse(TM) DNA vaccine platform, the
company's Vaxfectin(TM) adjuvant, or any other product candidates being
developed by Vical, its collaborators or licensees will be shown to be safe
and effective in clinical trials; the timing, nature and cost of clinical
trials; whether the company will achieve levels of revenues and control
expenses to meet projected financial performance; and additional risks set
forth in the company's filings with the Securities and Exchange Commission.
These forward-looking statements represent the company's judgment as of the
date of this release. The company disclaims, however, any intent or
obligation to update these forward-looking statements.
VICAL INCORPORATED
Selected Condensed Financial Information (Unaudited)
Statements of Operations Three Months Ended Six Months Ended
(in thousands, except per June 30, June 30,
share amounts) 2007 2006 2007 2006
Revenues:
Contract and grant revenue $2,980 $7,100 $3,830 $12,679
License and royalty revenue 131 156 536 192
Total revenues 3,111 7,256 4,366 12,871
Operating expenses:
Research and development 5,859 4,171 11,734 8,815
Manufacturing and
production 4,216 4,499 8,163 8,051
General and administrative 2,340 2,406 4,633 4,848
Total operating expenses 12,415 11,076 24,530 21,714
Loss from operations (9,304) (3,820) (20,164) (8,843)
Net investment income 1,107 576 2,370 1,126
Net loss $(8,197) $(3,244) $(17,794) $(7,717)
Basic and
'/>"/>
SOURCE Vical
 Copyright©2007 PR Newswire. | |
Page: 1 2 3 4 5 6 Related medicine technology :1.
Vaccine Can Prevent Cervical Cancer and Precancerous Lesions2.
Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix
Provides Excellent Protection Against Lesions Caused by Most Common
Cancer-Causing Virus Types3.
Vical Licensee AnGes MG Announces Positive Results of Phase 3
Angiogenesis Trial in Japan4.
Vical Interim Clinical Results Demonstrate Safety and Tolerability
of Inovio Biomedicals Electroporation DNA Delivery Technology5.
Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides
Sustained Immune Response in 100 Percent of Women up to 55 Years of
Age6.
Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA
Vaccine Performance; Yields Antibody Responses Comparable to
Electroporation Without Tolerability Issues7.
New England Journal of Medicine Publishes New Data on Gardasil,
Mercks Cervical Cancer Vaccine8.
Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100
Percent Protection Against Precancerous Lesions Caused By
Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than
Five Years9.
Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With
Seasonal Influenza Vaccine10.
Nventa Announces Presentation of Positive HspE7 Data from
NCI-Sponsored Clinical Trial in Cervical Dysplasia11.
Corgenix Reports New Clinical Data Correlating AtherOx Technology
With Vascular Disease